Duchesnay executive vice-president Eric Gervais said, "We are excited to enable expectant mothers within the Israeli market to have access to a proven safe and effective pharmacological treatment for NVP."
Tzamal will distribute the antinauseant and antiemetic drug for the management of nausea and vomiting of pregnancy (NVP) across the region.
Tzamal BioPharma, the pharmaceutical arm of Tzamal Medical, CEO E. Steinberg said, "Diclectin, as a delayed release combination proved its impeccable efficacy and safety in North America / Canada for years and as such recommended as first choice by both the Society Obstetricians and Gynaecologists of Canada (SOGC) and the American College of Obstetricians and Gynaecologists (ACOG)."
The Israeli MOH will approve the Diclectin as the first drug to address NVP based on the available clinical and safety data, according to Tzamal.